Advances in anti-tumor drug research based on reactive oxygen regulation
10.16438/j.0513-4870.2020-0281
- VernacularTitle:基于活性氧调控的抗肿瘤药物研究进展
- Author:
Yi MOU
1
;
Shuai WEN
1
;
Xin-xing GAO
1
;
Rui ZHANG
1
;
Yan WANG
1
;
Zheng-yu JIANG
2
Author Information
1. College of Pharmacy and Chemistry and Chemical Engineering, Taizhou University, Taizhou 225300, China
2. Jiangsu Key Laboratory of Drug Design and Optimization, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
- Publication Type:Research Article
- Keywords:
reactive oxygen species;
cancer chemotherapy;
redox balance;
glutathione;
Nrf2
- From:
Acta Pharmaceutica Sinica
2020;55(7):1453-1465
- CountryChina
- Language:Chinese
-
Abstract:
Reactive oxygen species (ROS) which were partial metabolites of oxygen are highly reactive. Different concentrations of ROS have different effects on tumor development. Tumor cells have a high level of reactive oxygen species. The antioxidant system of tumor is in highly activated state, and thus modulation of reactive oxygen species levels could be an effective strategy to target cancer cells. Treatment with small molecules that disrupt the redox balance can kill tumor cells first. This paper outlines the main ideas of developing anti-tumor drugs based on reactive oxygen species regulation, and summarizes the representative drugs and research progress according to the mechanism of action, in an effort to suggest potential reference and ideas for developing anti-tumor drugs based on reactive oxygen species regulation.
